NephroSant Publishes Real-World Evidence Showing Potential to Improve the Detection of Early Rejection Events with QSant
/PRNewswire/ -- NephroSant™ a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a...
Source: prnewswire.com